Details

Autor(en) / Beteiligte

• Loechelt, Brett J.
• Boulware, David
• Green, Michael
• Baden, Lindsey R.
• Gottlieb, Peter
• Krause-Steinrauf, Heidi
• Weinberg, Adriana

Titel

Epstein-Barr and Other Herpesvirus Infections in Patients With Early Onset Type 1 Diabetes Treated With Daclizumab and Mycophenolate Mofetil

Ist Teil von

• Clinical infectious diseases, 2013-01, Vol.56 (2), p.248-254

Ort / Verlag

Oxford: Oxford University Press

Erscheinungsjahr

2013

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Background. We assessed the morbidity of herpesviruses in patients with type 1 diabetes mellitus (T1D) enrolled in immunosuppressive treatment studies. Methods. Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV), and varicella zoster virus (VZV) infections were monitored in 126 participants of a randomized, double-blind, placebo-controlled study of daclizumab (DZB) and mycophenolate mofetil (MMF) including DZB + MMF + , DZB − MMF + , DZB + MMF − , and DZB − MMF − . During the 2-year follow-up, herpesviral infections were monitored clinically, by serology and blood DNA polymerase chain reaction. Results. Among 57 baseline EBV-seronegative participants, 9 developed EBV primary infections, including 2 with infectious mononucleosis syndrome. There were no appreciable differences in the course of the primary EBV infections across treatment groups. Among 69 baseline EBV-seropositive participants, 22 had virologic reactivations, including 1 symptomatic DZB − MMF + subject. Compared with 7 DZB − MMF − EBV reactivators, the 9 DZB + MMF + reactivators tended to have more prolonged viremia (11.4 vs 4.4 months; P = .06) and higher cumulative viral burden (14.2 vs 12.5 log EBV copies/mL; P = .06). Four of 85 baseline CMV-seronegative subjects developed asymptomatic primary CMV infections. There were no CMV reactivations. Of 30 baseline HSV-seropositive subjects, 8 developed ≥1 episode of herpes labialis; 1 subject had a primary HSV infection; and 1 subject without baseline serology information had a new diagnosis of genital HSV. There were no significant differences in the incidence of HSV recurrences across treatment groups. Of 100 baseline VZV-seropositive subjects, 1 DZB − MMF − subject developed herpes zoster and 1 DZB − MMF + subject had Bell's palsy possibly related to VZV. Conclusions. The use of DZB alone or in combination with MMF was not associated with increased morbidity due to herpesviruses.